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TOMMY TSUNG YING SHIH
Abstract
Taiwan's competitiveness in the global arena has often been attributed to the 
country's dynamic small and medium-sized enterprises (SMEs). In the most 
recent decade, the Taiwanese government has increased support to innovative 
SMEs, and with the emergence of new ﬁelds such as biotechnology, compa-
nies with highly innovation-driven agendas are surfacing. The innovation 
focus provides not only new opportunities but also challenges for Taiwanese 
SMEs. In this article I aim to increase the understanding of how national and 
global forces affect SME innovation in Taiwan. To this end, I use an indus-
trial network approach to trace the national and global interdependencies 
that follow the network of a Taiwanese SME in the biopharmaceutical sector. 
Keywords: SME, innovation, network, Taiwan, triangulation
Introduction
Taiwan's economic development is an impressive story. In just a few 
decades, the country has transformed itself from an agrarian society into 
an advanced high-tech economy (World Bank 1993; Amsden & Chu 2003). 
This transformation is highly associated with the country's dynamic 
small and medium-sized enterprises (MOEA 2010). During the 1970s 
and 1980s, when Taiwan commenced the transition into high-tech ﬁelds 
such as electronics and semiconductors, the SMEs were in the forefront 
of the global expansion (Chang, Shih & Hsu 1994; Mathews & Cho 2000). 
In the 1990s, with the emergence of the Taiwanese biotechnology sector, 
SMEs were yet again at the centre of attention. Although some SMEs 
have managed to develop new products and technologies, they have 
had difﬁculty ﬁnding markets, local as well as global, for their products 
(Hsu, Shyu & Tzeng 2005). For example, in 2007, the production output 
of the biotechnology industry was valued at roughly 6 per cent of what 
was produced in the semiconductor sector (MOEA 2008). Some observ-
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ers argue that such a number illustrates the failure of biotechnology in 
Taiwan (Hsu et al. 2005). Others claim that it is too early to judge how 
this industry will develop in the future (Wong 2005). Regardless, the 
Taiwanese government has continued to heavily support the build-up 
of a homegrown biotechnology industry. This effort is contingent on the 
creation of innovative capabilities among SMEs and their integration into 
global production networks (Ernst 2010; MOEA 2007). Hence, the recent 
developments are guided by a proactive government policy that seeks 
to indigenize innovation. By promoting the public research system, sup-
porting SMEs and introducing various technology transfer mechanisms, 
the Taiwanese government has aimed to build local innovation networks 
(Dodgson, Mathews, Kastelle & Hu 2008). The subsequent step in this 
model is to aid these networks in establishing ties to global markets (Liu 
1993). The present study posits that the model oversimpliﬁes the issue 
of innovation development and commercialization.
Taiwanese SMEs in the biotechnology sector are, on the one hand, 
affected by a national policy environment, which seeks to indigenize 
innovation and retain investments within national borders. Taiwanese 
innovative SMEs, on the other hand, are already often embedded within 
global innovation networks (Ernst 2010). Hence the national environ-
ment can hamper innovative activities, as the logic of local industrial 
policy is frequently different from the logic of global innovation net-
works. Such conﬂicts are, however, not uncommon. Jacobsen (2010) 
points out that there has been a trend of decoupling the nation-state 
from the global community. This is a highly impractical practice, as 
SMEs innovate in a local-global environment. As Kneller (2010) notes, 
SMEs are particularly important in the upstream part of the global bio-
technology value chain. Hence, in order to understand SME innovation 
in the Taiwanese context, we need to not only understand the domestic 
forces at play but also the global forces that shape company behaviour. 
To investigate the interplay between global and local forces, and their 
effects on SME innovation, I build on the idea of triangulation proposed 
by Jacobsen (2010) and Chin (2010). According to Jacobsen (2010: 2), 
triangulation infers that 'the relationship between economic globalisa-
tion, national economics and a given societal context in which the two 
former are embedded is governed by various layers of interdependency'. 
In this study, I conceptualize the three dimensions through the lens of 
the industrial marketing approach (Håkansson & Snehota 1995). In this 
perspective, the social context is the network of actors within which an 
SME is embedded. As industrial networks stretch across national and 
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global boundaries, this also allows for the investigation of various lo-
cal and global forces that affect the innovative activities of a focal ﬁrm 
(Håkansson, Ford, Gadde, Snehota & Waluszewski 2009). 
The present study contributes to the empirical understanding of Tai-
wanese SME innovation in the biopharmaceutical sector. It also builds 
on the industrial marketing literature by developing a conception of how 
national and global forces affect SME innovation in a network environ-
ment. The global and local contexts represent two distinct environments, 
upon which the focal ﬁrm and its network are dependent in order to 
innovate. Hence, a separation of these two dimensions is relevant to 
understand how Taiwanese SMEs innovate. This article uses a single 
case study approach, following a Taiwanese biotechnology company, to 
illustrate SME innovation in the local–global context. The next section 
presents the theoretical framework, based on the industrial network ap-
proach. Thereafter I present the method, followed by the introduction 
of the empirical case study. The analysis then discusses the inﬂuences 
of national and global forces on the focal ﬁrm's innovative activities. 
Lastly, the ﬁndings and implications of this study are discussed. 
Theoretical Framework
Networks and SME Innovation
Innovation as an interactive phenomenon has been widely described 
(e.g. Lundvall 1988; Chesbrough 2003; Håkansson & Waluszewski 2007). 
This study approaches innovation in the SME context from an industrial 
network perspective (Ford, Gadde, Håkansson & Snehota 2003). Innova-
tion through networking is particularly important for SMEs as small size 
and lack of resources put them at a disadvantage in the development 
and commercialization of innovation. For example, SMEs frequently face 
difﬁculties in access to markets, capital and skilled labour (Kaufmann & 
Tödtling 2002; Harvie & Lee 2002; OECD 2010). As such, SMEs are often 
dependent on their networks for access to various resources involved in 
the development and commercialization of innovations (Fuller-Love & 
Thomas 2004). Hence, in the SME context, resource combinations beyond 
company borders are of particular importance as companies frequently 
lack the resources to single-handedly develop and commercialize in-
novations (Narula 2004). Moreover, as companies seek complementary 
resources they often ﬁnd themselves working with business and non-
business actors, both in the home country and abroad. Thus, a network 
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view can aid in explaining and illustrating interdependencies created 
between national and global forces in a societal context. This study 
investigates, in particular, the effects of global and national interde-
pendencies on SME innovation.
Tracing National and Global Interdependencies in a Network Context
This research is based on the industrial network approach (Håkansson 
1982). In this approach, a network is made up of three interrelated di-
mensions: actors, resources and activities (Håkansson & Snehota 1995). 
Interaction over time in a network establishes interdependencies and ad-
aptations that create imprints on both the human and material resources 
involved. This phenomenon, over the last few decades, has interested a 
great number of researchers (see e.g. Rosenberg 1994; van de Ven, Polley, 
Garud & Venkataraman 1999; Ford et al. 2003; Håkansson et al. 2009). 
With interdependencies in the business landscape as a focus, empirical 
investigations of the content and effect of this phenomenon have been car-
ried out, among others, by researchers related to the industrial network 
approach (e.g. Håkansson & Waluszewski, 2002; Waluszewski, Baraldi, 
Linné & Shih 2009; Strömsten & Håkansson 2007; Shih 2009).
In theory, industrial networks can extend endlessly; they are not 
geographically bounded (Ford, Gadde, Håkansson & Snehota 2002). 
Hence the different institutional logics (Thornton 2002) that a ﬁrm 
encounters through its network activities derive from national as well 
as global environments. This study examines the national institutional 
context as well as the global industrial networks within which the fo-
cal SME is embedded. These two contexts form a speciﬁc conception 
of the national and global forces that affect SME innovation in Taiwan. 
On the one hand, a company is inﬂuenced by norms, rules and insti-
tutionalized ideas from the national context (Forsgren 2008). On the 
other, a company has to confront the norms and value systems of global 
production networks (Levy 2008). Embedded within these forces, SMEs 
manage innovation and confront the logics of institutions, business and 
non-business actors. 
Analytical Framework
The analytical framework traces the network relationships, i.e. the 
actor bonds, resource combinations and the activity links, of a focal 
company (Håkansson & Snehota 1995). The network of actors is then 
divided into actors that the focal ﬁrm relates to in a national context and 
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a global context respectively. The present study posits that the different 
environments pose and offer different challenges and opportunities for 
the focal ﬁrm, that is, the norms and institutionalized ideas and logics 
within each environment are different to a greater or lesser degree 
(DiMaggio & Powell 1983). Through the bifurcated distinction, the 
interdependencies created in the two contexts can be separated, but 
they also aid in understanding how the different environments affect 
the focal company's innovative activities. The ﬁgure above illustrates 
the analytical framework.
Method
This paper adopts a single case study methodology. Case studies enable 
the research of details on activities and relationships (Holmlund 2004). 
In the industrial network tradition, case studies are heavily utilized to 
exemplify diverse empirical phenomenon. Easton (1998) argues that 
the usefulness is due to the richness of the picture produced by case 
research and the approach is suited to handle the complexity of network 
links among actors. Researchers can also suitably use case studies when 
exploring interaction and tracing the development of network changes 
over time (Dubois and Araujo 2004). 
FIGURE 1: Analytical framework
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The case portrays the innovation journey of a Taiwanese biotechnol-
ogy company and the challenges and opportunities it faces in its innova-
tion environment. The case ﬁndings will be used in a broader discussion 
on the innovation environment of Taiwanese biopharmaceutical 
companies. The empirical material that the case study builds on was 
collected in the period 2004–2008. In the case study I use so-called 'rich 
descriptions' (Walsham 1995) by combining interviews with secondary 
material retrieved from the company and its website, and other printed 
material. Interviews are the major source of information. This paper is 
based on 24 face-to-face interviews of 17 respondents. The average du-
ration of the interviews was approximately one hour and all interviews 
were conducted in Taiwan. The respondents interviewed had different 
organizational afﬁliations, including policy organizations, universities, 
research institutes and companies. Respondents were identiﬁed through 
snowball sampling. The secondary sources include materials such as 
ofﬁcial policy documents, articles from academic journals and news-
papers, industry reports, websites, transcribed speeches and statistical 
material. The secondary sources identify events and establish timelines 
and give varied perspectives of the development processes studied. 
Sometimes they have functioned as a single source of information to 
describe a development process and give voice to resources. Other 
times the secondary sources have helped to deepen and substantiate 
the picture given by interviewees.
Case Study
The case study focuses on the development and commercialization of 
biopharmaceutical drugs in Taiwan. The ﬁrst section describes how the 
focal company innovates in the Taiwanese context. The second section 
focuses on its innovative activities in a global context.
The focal actor of this study is a medium-sized biopharmaceutical 
company with 60 employees (2008), the Taiwan Liposome Company 
(hereafter TLC). The company was established in 1997 as a university 
start-up and its main business activities are liposome drug delivery and 
proprietary drug development. Liposome drug delivery centres on mak-
ing existing pharmaceutical drugs more efﬁcient by ﬁnding solutions 
to improve the ways the human body can absorb the drug (Haumann 
1995). Through this business idea, TLC, together with partner companies, 
has developed a generic pharmaceutical drug for the Taiwanese market. 
The company has four additional drug candidates in its development 
pipeline. Recently TLC also moved into novel drug development, i.e. 
42 ____________________ The Copenhagen Journal of Asian Studies 30(1)•2012
Tommy Tsung Ying Shih ____________________________________________________
the development of patentable drug candidates through a partnership 
with foreign actors. Although drug innovation is desired and supported 
by Taiwanese policymakers, the established healthcare and regulative 
systems are not able or willing to bring forward novel drugs in Taiwan. 
The following case illustrates the inﬂuences of national and global forces, 
including the interplay between them, on TLC's innovative activities.
Development of Biopharmaceutical Drugs Embedded in a 
National Ambition to Create a Biotechnology Industry
The biotechnology sector has since the mid-1990s been on the Taiwanese 
government's list of potential industries that can move Taiwan into the 
league of advanced innovative nations. This focus on biotechnology has 
meant extensive support to basic research as well as to the industrial sec-
tor. Up to 2007, 265 companies had been established in the biotechnology 
sector, focusing on areas such as drug development, medical technol-
ogy and clinical testing (MOEA 2008). Such a development coincides 
with the expansion of science parks and the establishment of research 
institutes aimed at developing certain ﬁelds of biotechnology relevant 
for Taiwan and its industrial sector. It is within this environment that 
TLC was formed in 1997 by Dr Keelung Hong. The company started 
out with a group of ﬁve researchers at the National Taiwan University, 
led by Hong. The initial idea of the group was to encapsulate a drug 
for cancer based on the drug delivery system that the group had devel-
oped. The choice of what off-patent drug to apply the delivery system 
to was made by Hong. His experience with earlier drug developments 
in the United States, closely related to what TLC was attempting, was 
beneﬁcial for the company's growth. 
At this time only a handful of Taiwanese companies were involved 
in drug development, not including the generic drug manufacturers. 
TLC raised start-up capital mainly from friends and family, but was 
unsuccessful in obtaining funding from Taiwanese government sources. 
The main reason why TLC did not receive any ﬁnancial support from 
the government was due to a perceived lack of novelty of the proposed 
project. Nonetheless, TLC managed to go through pre-clinical trials 
with a small purse by utilizing university laboratories and Hong's 
prior experience from a similar project. After the necessary regulatory 
approvals of safety and efﬁcacy had been attained, the next step was 
to start clinical trials. The Taiwanese regulatory environment and the 
institutional framework are streamlined for such tests of generic drugs, 
and few obstacles are to be found if approval from the authorities ex-
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ists. However, a problem was identiﬁed in the lack of connections to 
pharmaceutical producers, as a large quantity of the active ingredient 
of the drug was needed.
The problem was eventually solved when TLC entered into a partner-
ship with one of the largest local pharmaceutical producers, TTY Phar-
maceuticals. The company licensed the rights to TLC's drug candidate 
and also continued with clinical testing. By the millennium shift, TTY 
had ﬁnished the clinical trials and introduced the drug on the Taiwanese 
market after the Taiwanese drug authorities had approved it for use. TLC 
followed this line of developing generic drugs for the subsequent drug 
candidates. Two more drug candidates were developed and licensed 
by TLC in a similar fashion. For this development, Taiwan's Ministry of 
Economic Affairs gave TLC an award as 'high-tech entrepreneur of the 
year' in 2002. TLC represented an example of how a national network of 
universities, government research institutes and industrial actors jointly 
had developed and commercialized pharmaceutical drugs. By 2008, 
TLC had with its domestic partners launched one biopharmaceutical 
drug on the Taiwanese market and four others were being developed 
(see Table 1).
TABLE 1: Product pipeline, Taiwan Liposome Company (2008)
Product Technology Phase Partnerships
Lipo 
Dox
Underlying drug: 
Doxorubicin. Liposome 
formulation developed by 
Keelung Hong
Out on market, approved for 
treatment of ovarian cancer and 
Kaposi's sarcoma by the DOH 
2002. Sales of 90 million NTD 
(2004) 
Licensed to 
TTY Pharma-
ceuticals for 
production 
and sales  
Lipo AB Underlying drug: 
Amphotericin B Liposome 
formulation developed by 
Keelung Hong
Clinical trials phase 2 Licensed to 
TTY Pharma-
ceuticals for 
production 
and sales
Nano 
VNB
Underlying drug: 
Vinorelbine NanoX, licensed 
from Hermes (Keelung Hong 
co-developer)
Clinical trials phase 1 Licensed to 
Nankuang 
Pharmaceu-
ticals
TLC 188 Dual function technology, 
NCE California Paciﬁc Medi-
cal Center owner of the patent 
(Yang) 
Filed patent 2005, Filed for IND 
Q3, 2006. Currently in pre-clini-
cal trials
No
TLC 
X88
Dual function technology, 
NCE
Underlying drug: 
Camptosar: Camptothecin 
analogue, California Paciﬁc 
Medical Center owner of the 
patent. 
(Yang) 
Pre-clinical No
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However, the story does not end here and the picture is not as rosy as 
it appears. The companies involved in the discovery and development 
of novel drugs in Taiwan are still few in number. The local pharmaceu-
tical industry consists mainly of generic drug manufacturers catering 
predominantly for a local market. They generate their main income 
from drug reimbursements by the national health insurance system. 
With the health insurance system as the main source of income for a 
large number of local generic drug manufacturers, they are heavily 
dependent on the prescribers of drugs. Taiwanese healthcare providers 
such as hospitals and clinics have usually formed stable relationships 
with the generic drug manufacturers. Due to the healthcare providers' 
power on the local market governing the prescription of drugs, the drug 
manufacturers are in a dependent position. They often sell drugs to the 
healthcare providers at a discounted price. The margin between the 
selling price and what the national health insurance system reimburses 
goes directly to the healthcare providers. Thus, the healthcare provid-
ers have tended to prioritize proﬁts ahead of efﬁcacy. This means that 
novel drug innovations that sell at a premium are not easily embedded 
in the existing healthcare system. 
However, attempts to change the system are ongoing. For example, the 
Taiwanese government's measures to reform the inefﬁcient reimburse-
ment system have resulted in a decrease in the number of generic drug 
manufacturers. In 2006, the pharmaceutical sector had decreased by 51 
companies from a year earlier, to 368 companies. At the same time, the 
number of research-based pharmaceutical and biotechnology companies 
developing novel drugs or modifying existing drugs for new uses has 
increased in the last decade. However, no Taiwanese company has yet 
developed and produced a novel drug (MOEA 2008). To understand this 
challenge I will continue by broadening the picture by discussing the 
challenges and opportunities that TLC has faced in the global context.  
Transcending National Boundaries in the Search for Product 
Innovation
The history of liposome technology starts in Cambridge, England, in 
1965, where it was discovered by a group of scientists. In the 1970s 
scholars, mostly in the United States, especially the San Francisco/Silicon 
Valley area, suggested that these discoveries could lead to the develop-
ment of new ways of delivering drugs. However, it was not until the 
1990s that clinical applications developed by a handful of American bio-
technology companies became available. It was within this environment 
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that Hong was active as a researcher and industrial consultant from the 
1970s to the 1990s. Hence he had acquired experience of clinical drug 
development and was also knowledgeable of the frontiers of liposome 
science. When he returned to Taiwan to teach, and later form TLC, he 
was a pioneer and authority within liposome research and business. 
This also meant that TLC was from the beginning embedded in a global 
research network. TLC's knowledge of liposome science and clinical 
applications were derived from this network. 
The assistance from the policy-supported Taiwanese environment 
was related to cheap laboratory and ofﬁce space at the National Taiwan 
University and Nankang Software Park in Taipei. Taiwan also provided 
for the production of drugs and clinical testing. The actual knowledge 
of drug development and the ambition to innovate was, however, 
strongly embedded in a global network. For example, to develop or 
acquire multiple technology platforms was an essential strategy to be 
able to develop more drugs. When TLC pursued such a strategy in the 
beginning of the new millennium, the company sought alliances in the 
United States. Neither Taiwanese companies nor the public research 
system had any extensive experience with drug delivery systems. 
Moreover, the assistance offered from the Nankang incubation centre 
and the Taiwanese government research institutes was limited. The 
main technology partner for TLC was Hermes Biosciences located in 
San Francisco. Hong had co-founded Hermes Biosciences in 1998 and 
licensed the rights to use a proprietary technology platform from the 
company. The technology could be combined with existing drugs as 
well as new chemical compounds.
In 2005 TLC moved in the new direction of novel drug development. 
The company ﬁled two new patents, which would serve as a foundation 
for a new line of novel drug candidates. The two patents had originally 
been developed at California Paciﬁc Medical Center (CPMC) from 
discoveries made by Professor Li Xi Yang. At CPMC, Yang conducted 
research on a group of anti-cancer agents. The research had resulted 
in the synthesis of a new chemical compound classiﬁed as a novel dis-
covery. Yang agreed to become a vice president of TLC and head the 
company's American subsidiary. The mission of the subsidiary, TLC 
Biopharmaceuticals, was to develop a new line of novel drugs, founded 
on Yang's discovery of a new compound and TLC's proprietary liposome 
technology. The decision to move development to the United States was 
also a conscious choice to overcome the bottlenecks in Taiwan's drug 
approval system. While generic drugs enjoy a streamlined process from 
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clinical testing to marketing, this is not the case for novel drugs in Tai-
wan. No novel drugs have ever been approved in Taiwan. This creates 
a dilemma, as no established routines exist, resulting in difﬁculties in 
evaluating new drug applications. To handle novel drug developments 
in the United States is therefore a better choice for drug discovery and 
developing companies. 
Although TLC's establishment of an American subsidiary increased 
costs considerably, it had several advantages. The company could 
conduct innovative activities in an environment with a developed in-
frastructure and regulatory system for drug development. Even before 
establishing the American subsidiary, TLC frequently interacted with 
US-based companies, research organizations and researchers. The head-
quarters of the company is still, however, in Taiwan, where expenses 
are much lower than in the United States. In Taiwan, the company has 
been able to keep the costs down through lower salary levels and low 
facility costs. Conducting clinical trials in Taiwan has also been favour-
able as patients are generally positive towards trying out new drugs 
and the government is aiming to establish Taiwan as a clinical trials 
centre for Asia. Hence, TLC plans to keep the main research and devel-
opment activities in the US, where the experienced biopharmaceutical 
researchers are found. It is also easier to get a novel drug approved in 
the United States than in Taiwan, due to the experience of the Food and 
Drug Administration in evaluating novel drugs. The production of the 
drug and the active ingredients will be done in Taiwan, through the 
established connections with Taiwanese pharmaceutical companies. 
In 2010, TLC also established TLC Biopharmaceuticals BV, a subsidi-
ary located in Leiden, the Netherlands, to be able to work within the 
European regulatory system and develop new drugs for the European 
market. As in the United States, Europe has an advanced drug develop-
ment system conducive for drug innovation. The recent developments 
and focus on innovative drug research and development have enabled 
TLC to establish a partnership with TEVA Pharmaceutical Industries, 
the largest generic drug manufacturer in the world. The relationship 
allows TLC to embed within a global production network.
Analysis
The following analysis describes the network in which TLC is embedded 
in order to innovate. Figure 2 portrays the company's existing network 
in global and national contexts. 
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In the national context, TLC focuses on generic drug development 
and incremental innovation. The support from the government enables 
the company to pursue development of drugs that can easily embed 
within the established structures. However, the established actors in 
the Taiwanese pharmaceutical sector stiﬂe radical innovation through 
their heavy investments in present structures. The dominant business 
model in the pharmaceutical industry is to provide generic drugs to 
healthcare providers at a low price. In such an environment there are 
few possibilities and low tolerance to innovate outside of the system. 
The environment in Taiwan does not allow for any innovation that 
drastically changes the structure of the sector. 
To pursue radical innovation, TLC sought assistance outside of the 
national environment. In the United States, knowledge, technology and 
a conducive institutional context were available. The founder's prior 
scientiﬁc and business contacts in the US enabled TLC to embed within 
the American drug development system. The choice to circumvent the 
bottlenecks in Taiwan by moving to an environment conducive for radi-
cal innovation was a necessary step. However, this also puts TLC in a 
more vulnerable position as the company faces higher cost structures 
and lack of legitimacy.
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FIGURE 2: TLC's Innovation Network in a National and Global Context
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The interplay between the two environments becomes in this situa-
tion an important aspect. The low cost of production and clinical testing 
in Taiwan remains an important part of TLC's business model. This 
part integrates with the development of novel drugs in a global envi-
ronment that allows for radical innovation. TLC's establishment of a 
business model that can combine radical innovation with incremental 
innovation has helped the company to embed within a global produc-
tion network.
Discussion and Conclusions
In the last decade, Taiwan has focused on replacing the label 'made 
in Taiwan' with 'innovated in Taiwan'. To facilitate this transition, the 
Taiwanese government has supported and guided research organiza-
tions and companies in their innovative activities. SMEs play an integral 
role in developing and commercializing innovations, particularly in 
new industrial sectors such as biotechnology. Their success or failure 
in innovation is not only affected by internal company factors but also 
by the larger environment in which they act. This article has followed 
a Taiwanese SME in the development of biopharmaceutical drugs. 
Although the company is not necessarily representative of Taiwanese 
high-tech SMEs, the case demonstrates how national and global environ-
ments impact the development and commercialization of innovations. 
Industrial network theory, as an analytical lens integrating national and 
global forces, aids in increasing the understanding of the challenges and 
opportunities Taiwanese SMEs face in their innovation journeys. 
An apparent challenge in the national context as illustrated in this 
case, is the conﬂict between the policy aim of supporting innovative 
SMEs in the biotechnology industry on the one hand, and the im-
mature drug approval system in Taiwan on the other. It is evident 
in this regard that social policy and industrial policy have not been 
considered together. While government promotion of innovation has 
strengthened the development pipelines of small and medium-sized 
drug developers, the drug approval system and national health system 
hamper biopharmaceutical innovation. This obvious conﬂict makes it 
difﬁcult for Taiwanese drug developers to develop innovative drugs 
for a domestic market. The complexity of innovation, however, goes 
well beyond this simple clash. The focal company's innovation journey 
is highly embedded in a network that is global. The case suggests that 
while globalization intensiﬁes competitive pressure on SMEs in national 
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and global arenas, it also gives SMEs opportunities to access resources 
transcending national borders. 
Thus, globalization is a double-edged sword that requires explicit 
attention. In the Taiwanese policy context, this phenomenon is still not 
well understood.  Let us take the example of Taiwanese policymakers' 
endeavour to build up national innovative capacity, where it is envi-
sioned that the national supply of ideas and inventions are to be used 
and commercialized by local SMEs. However, how does the observation 
that innovation networks are highly global come into practice in this 
idealized desire to achieve independent national innovation? From the 
case study, it is evident that it is not easy for policymakers to control 
or dictate the geographical dispersion and direction of innovation. Do-
ing so would likely be counterproductive, as the nature of innovation 
is characterized by a high degree of serendipity. Hence, if we take a 
more descriptive stance rather than a normative one, we can understand 
through the applied framework the ramiﬁcations of national SME policy 
in the context of globalization.
 I have in this article aimed to increase the understanding of how 
national and global forces affect the environment for SME innovation in 
Taiwan. It was observed that national innovation policy often conﬂates 
innovative capability with innovation per se. For example, effective 
intellectual property regimes and the government's commitment to 
support local upstream research and SMEs, for instance, are seen to be 
key policy instruments to facilitate technological innovation processes. 
Research and development is highly global in nature and putting more 
effort into supporting global developing networks could beneﬁt policy 
attempts to strengthen national innovation. However, as this study il-
lustrates, research and development is only one part of the innovation 
journey; policymakers also need to consider that an innovation needs 
to be embedded in streamlined regulatory and market systems. The 
contexts seem to be driven by different institutional logics, and are also 
less affected by the forces of globalization until recently in Taiwan.
Lately, pharmaceutical suppliers have viewed the emergence of 
innovative SMEs as a channel to gain competitiveness and enter for-
eign markets. This offers biotechnology SMEs an opportunity to com-
mercialize their discoveries. Nonetheless, for the biotechnology SME 
environment to be truly conducive to innovation, the major discord 
with the national market setting needs to be remedied. This will be a 
considerable challenge as this setting is characterized by well-established 
structures with social and economic relationships negating the efforts 
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of SMEs to innovate. Hence for SME s to innovate it is necessity to ﬁnd 
opportunities to work within the national context, but also to be able 
to transcend the constraints that are posed by this environment. As in 
the case of the focal company in this study, constraints led the company 
to seek opportunities outside of the national context and to ﬁnds ways 
to combine national and global opportunities. This is a challenge but 
also a necessity for companies to be truly innovative in the Taiwanese 
biopharmaceutical sector.
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